Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, in order to know the gender of fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology Nike VaporMax Flyknit Soldes , transplantation and infectious diseases.
The Cell-Free DNA Testing Market is segmented on basis of its application, types and region. On basis of application the market is segmented into oncology, gynecology and transplantation. By type, the market is further segmented into donor derived cell free DNA (ddcfDNA), circulating cell-free tumor DNA (ctDNA) and cell-free fetal DNA (NIPT). Donor-derived cell-free DNA testing examines the graft rejection in transplanted patient by recognizing the absence or presence of donor DNA in the bloodstream. In ctDNA testing, circulating tumor DNA in urine Nike VaporMax Flyknit Meilleur Prix , saliva or blood of tumor patients is examined to detect mutation. In prenatal testing, the chromosomal abnormality is identified in the fetus by collection of blood sample from pregnant women who carry DNA of that fetus.
The cell-free fetal DNA market has a major share in the market due to increased number of pregnancies following to it is the circulating cell-free tumor DNA market and later the donor derived cell-free DNA market. In the region wise segmentation, North America region had the largest revenue in 2015 due to majority of tests launched and adaptation of advanced technologies in screening techniques. Following North America is Europe and Asia Pacific which are also the fastest growing market due to blooming economy and improving healthcare infrastructure and rising prevalence of diseases in these regions. The potential of cell-free DNA testing market has attracted many biotechnology and pharmaceutical firms by acquiring other major firms or by launching novel tests.
Request to View Brochure of Report –
;rep_id=14162
Increased incidences of diseases like chromosomal abnormalities due to increase in maternal age, changing lifestyle, unhealthy diet habits and rising prevalence of cancer, also in addition to it increasing healthcare expenditure and rising healthcare awareness are the reasons driving the cell-free DNA market. However Nike VaporMax Flyknit Homme , there are some other factors such as lack of skilled healthcare professionals, high test cost, non-affordability in low income countries, ethical issues related to genetic testing, lack of standardization, unfavorable reimbursement policies and legal and regulatory guidelines some of the reasons hampering the growth of the market.
Various companies are coming up with new software and improved sequencing technologies which has improved the test quality with accurate and rapid results. Some of the leading players in cell-free DNA testing market are Agilent Technology Nike VaporMax Flyknit Femme , Allenex AB, Biocept, Inc., Biodesix, Inc., CareDx Nike VaporMax Flyknit Utility , Inc. Guardant Health, Inc., Illumania, Inc., Inivated Limited, Natera Nike VaporMax Flyknit Moc , Inc., Quest Diagnostics, Roche Holdings AG, Sequenom, Inc. and Trovagene, Inc. The global cell-free DNA testing market is a competitive market and all the players are involved in developing new assays by mergers and acquisitions In order to sustain themselves in the market and maintain their market share. For instance Nike Air VaporMax Flyknit , Roche Holdings AG received U.S. FDA approval for its newly launched ctDNA test Cobas which is approved for blood based genetic tests. Roche also entered the NIPT market with acquisition of Ariosa diagnostics. CareDx, Inc., acquired Allenex AB for its new developments in donor derived Cell-Free DNA tests for kidney and heart transplant patients.
Request to View ToC of the report –
;rep_id=14162 Home Loan Interest Rates by Major Banks
Posted by anuragmishra on January 2nd, 2017
In the period of recession most of the banks offer home loan interest rates, car loans, and personal loans on lower interest rates. Recently Nike VaporMax Flyknit , SBI announced to lower interest rates for its special home loan interest rates for new borrowers at 8% for one year. After the one year interest rates will reset again.
SBI has announced special home loan interest rates for its existing customer also which is known as "SBI Lifestyle Loan". SBI Lifestyle loan offers up to Rs. 5 lakh. On the loan amounts charge rate would be 8% per annum for one year period. For above Rs. 5 lakh to 20 lakh SBI offers "SBI Special Home Loan Interest Rates scheme". According to the scheme an existing customer can take loans at 8% rate for one year and originally contracted rate will be applicable after having completed the one year.
ICICI is another second largest bank of India which offers home loan interest rates on lower interest rate. It has cut about 25-50 bps charge rates for its new customer. However, it has higher interest rates from SBI and HDFC banks. Its current interest rates would be 9.75% for 20 lakh loan amounts. For above 20-30 lakh home loan amounts home loan interest rates would be 10% and for more than 30 lakh it would be 11.5%.
The ICICI bank has not cut interest rates for its existing customers.
On the other hand Canara Bank has fixed the interest rates for 20 years with different rates on the different slabs.